Key takeaway: Nephrocare Health Services Limited (NephroPlus) reported its Q1 FY27 financial results, highlighting a revenue increase of 23.7% year-on-year to ₹281.8 crore, driven by a 13.3% rise in treatments to 10.31 lakh and a 13.0% increase in guests to 38,262. Adjusted EBITDA grew 30.7% to ₹65.1 crore, with an adjusted EBITDA margin of 23.1%, reflecting operational leverage. The company emphasized its strategic expansion, reaching 550 clinics across five countries, and launched the NephroPlus International Dialysis Academy to address staffing challenges. Management noted the shift from unorganized to organized dialysis services in India as a significant growth opportunity. The presentation also detailed ongoing initiatives to enhance clinical outcomes and patient care, alongside a commitment to maintaining profitability while expanding its international footprint.

Key takeaway: Nephrocare Health Services Limited (NephroPlus) held its Q4 and FY26 earnings conference call on May 20, 2026, where management discussed the company's performance and growth strategies. For FY26, revenue grew by 32% to INR998.8 crores, with adjusted EBITDA increasing by 37% to INR238.2 crores. The number of active patients, referred to as 'guests', rose by 12% to 37,000, while total treatments increased by 17%. Management highlighted the unique characteristics of the dialysis business, emphasizing the need for scale and operational focus. They outlined three growth levers: increasing volume in existing clinics, rolling up clinics in current markets, and expanding into new geographies. Management set a revenue CAGR goal of 15% to 20% over the next three to four years. They also noted investments in technology, including the use of AI to enhance operational efficiency. The call concluded with a Q&A session addressing various operational and financial queries.

Key takeaway: Nephrocare Health Services Limited (NephroPlus) reported its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company achieved a revenue of ₹998.8 crore for FY26, reflecting a 32.2% year-over-year increase, driven by a 16.6% rise in treatment volumes. Adjusted EBITDA for the year was ₹238.1 crore, up 37.6% YoY. The presentation highlighted a favorable shift towards international markets, which contributed 41.8% of revenue in FY26. NephroPlus served over 36,000 patients across 520 clinics in 325 cities. Management emphasized the importance of digital innovation and operational efficiency in scaling the business. The company also noted its commitment to patient-centric care and maintaining high clinical standards. The presentation included various awards and recognitions received by NephroPlus, underscoring its leadership in the dialysis sector.

Key takeaway: Nephrocare Health Services Limited held its first earnings conference call on February 11, 2026, to discuss its Q3 and nine-month financial results for FY26. Management highlighted the growth of the Indian healthcare sector, particularly in dialysis, driven by rising non-communicable diseases. They noted the unique characteristics of the dialysis business, emphasizing the need for a widespread network of clinics to provide accessible care. NephroPlus reported a 32% year-on-year revenue growth in Q3 and a 37% increase for the nine-month period. The company aims for a revenue CAGR of 15%-20% over the next 3-4 years, focusing on expanding its clinic network and entering new markets. Management also discussed the importance of patient-centric care and operational efficiency, which have contributed to improved profitability and market share. The call concluded with a Q&A session addressing various operational and strategic queries from investors.